Doctors say active monitoring, hormone therapy and newer focal treatments are reshaping care decisions for men.

For the first time ever, NTNU researchers have identified new characteristics of aggressive prostate cancer. The research lays a foundation for the possibility that aggressive prostate cancer can ...

A trial evaluated the short-term oncologic efficacy of cooled focal therapy ablation using the ProFocal device in men with localized, intermediate-risk prostate cancer.

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...

The Miriam Hospital says it has treated the first patients in the world in two new clinical trials testing therapies for prostate cancer, offering local patients access to treatments years before they ...

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy (ADT), the disease often progresses to castration-resistant prostate cancer ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment. A recent ...

Professor Chad Mirkin found that the vaccine’s carefully organized structure dramatically boosts cancer-fighting immunity.